Published in Dermatol Clin on April 01, 2017
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med (2015) 3.25
Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res (2003) 3.07
Clinical practice. Vitiligo. N Engl J Med (2009) 2.72
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 2.24
Abatacept. Nat Rev Drug Discov (2006) 2.13
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol (2015) 2.05
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02
Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol (2008) 1.95
Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol (1991) 1.89
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc (1999) 1.58
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol (2009) 1.53
Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. J Invest Dermatol (2015) 1.52
Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology (1995) 1.51
A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
Inflammasome-Dependent Induction of Adaptive NK Cell Memory. Immunity (2016) 1.44
Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol (2002) 1.40
Vitiligo. Lancet (2015) 1.27
Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol (2015) 1.27
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol (2015) 1.20
Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol (2011) 1.15
NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A (2013) 1.12
Mechanisms regulating melanogenesis. An Bras Dermatol (2013) 1.07
Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol (1991) 1.04
Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol (2011) 1.04
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol (2014) 1.03
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol (2015) 1.00
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis (2004) 0.99
HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res (2011) 0.97
Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97
Ruxolitinib. Nat Rev Drug Discov (2012) 0.96
Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol (2004) 0.94
Melanins and melanogenesis: from pigment cells to human health and technological applications. Pigment Cell Melanoma Res (2015) 0.92
Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol (2007) 0.91
Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol (2002) 0.91
Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol (2003) 0.89
Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation. Dermatol Ther (2014) 0.89
Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol (2015) 0.88
The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol (2013) 0.88
Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One (2012) 0.88
A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol (2013) 0.88
Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol (2007) 0.88
Presence of epidermal allantoin further supports oxidative stress in vitiligo. Exp Dermatol (2008) 0.87
Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol (2016) 0.85
Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opin Drug Saf (2014) 0.83
Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med (2011) 0.83
Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J Invest Dermatol (2006) 0.83
Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol (2016) 0.83
Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol (2015) 0.82
Membrane lipid alterations as a possible basis for melanocyte degeneration in vitiligo. J Invest Dermatol (2007) 0.82
The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol (2011) 0.81
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med (2015) 0.81
Pseudocatalase and narrowband ultraviolet B for vitiligo: clearing the picture. Br J Dermatol (2009) 0.80
Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev (2016) 0.80
From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol (2008) 0.80
Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell Melanoma Res (2015) 0.79
Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci. Front Genet (2016) 0.78
Alternative Systemic Treatments for Vitiligo: A Review. Am J Clin Dermatol (2015) 0.76
Melanocyte Regeneration in Vitiligo Requires WNT beneath their Wings. J Invest Dermatol (2015) 0.76
Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo. Exp Dermatol (2016) 0.76
Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr (2016) 0.76
A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol (2017) 0.76
Differential diagnosis of idiopathic vitiligo. Part III: Occupational leukoderma. Cutis (1994) 0.75